CEQUA™ mechanism of delivery
Only CEQUA provides the highest FDA-approved concentration of cyclosporine (0.09%)1,2
Cyclosporine offers over a decade of proven efficacy as a dry eye medication and is the most widely prescribed treatment for the disease in the United States.2,3
Learn more about the CEQUA difference
Welcome to CEQUA–an innovative cyclosporine formulation with advanced NCELL technology for dry eye disease.
What makes CEQUA different?
CEQUA is a clear, uncolored solution that offers the highest concentration of cyclosporine approved by the FDA (for ocular use). The proven cyclosporine molecule is delivered with advanced proprietary NCELL technology for increased ocular penetration. Specifically, CEQUA increases tear production.
The proven efficacy of cyclosporine
The cyclosporine molecule has been used as an effective treatment for dry eye for many years.
In patients with ocular inflammation due to dry eye, cyclosporine helps restore tear production by acting as a partial immunomodulator. The exact mechanism of action is not known.
However, delivering the cyclosporine molecule to the eye has been challenging due to its poor aqueous solubility. Different approaches have been used to help overcome the solubility issue and deliver the cyclosporine molecule into the eye.
The benefits of NCELL technology
NCELL helps address the solubility challenges of cyclosporine with an innovative delivery system.
NCELL technology uses nanomicelles composed of a blend of polymers including polyoxyethylene hydrogenated castor oil 40, or HCO-40, and Octoxynol-40, or Oc-40.
The units of polymers self-assemble into a nanoscale aggregate via a thermodynamic process.
Once assembled, the polymers work together as a unit, or nanomicelle, with a hydrophilic outer layer and hydrophobic core.
The hydrophilic outer layer, which is compatible with the aqueous environment of the tear film, allows for transport through the tear film onto the ocular surface. At the same time, the hydrophobic core prevents the encapsulated cyclosporine from being released until after the nanomicelle penetrates the aqueous layer of the tear film.
The small size of the nanomicelles, which measure an average of 22 nanometers or approximately one three-thousandth the width of a human hair, helps facilitate the entry of cyclosporine into corneal and conjunctival cells. The nanomicelles penetrate the aqueous layer of the tear film and release the active cyclosporine molecules for penetration into ocular tissues.
Once released, cyclosporine gets to work to reduce inflammation, helping improve the ocular surface and increase tear production.
Enhanced penetration of CEQUA
CEQUA helps ensure that more of the cyclosporine molecule gets where it is needed.
In a single-dose, preclinical study vs a cyclosporine emulsion, a cyclosporine formulation with NCELL enabled nearly 3 times more of the molecule to penetrate the cornea, while allowing 1.6 times more of the molecule to penetrate the conjunctiva.
CEQUA offers an innovative formulation of cyclosporine with NCELL, resulting in increased penetration and delivery of the proven anti-inflammatory power of cyclosporine.
Prescribe CEQUA today so your patients can experience the benefits of NCELL for dry eye.
Indications and Usage
CEQUA (cyclosporine ophthalmic solution) 0.09% is a calcineurin inhibitor immunosuppressant indicated to increase tear production in patients with keratoconjunctivitis sicca (dry eye).
Important Safety Information
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: CEQUA should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of CEQUA ophthalmic solution.
The most common adverse reactions reported in greater than 5% of patients were pain on instillation of drops (22%) and conjunctival hyperemia (6%). Other adverse reactions reported in 1% to 5% of patients were blepharitis, eye irritation, headache, and urinary tract infection.
Please see the Full Prescribing Information.